MetaCap

Supernus Inc. (SUPN)

NASDAQ: SUPNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

28.61+0.26 (+0.92%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SUPN stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.76
Ex-dividend date
Nov 3, 2026
52-week range
25.92 – 42.81
Day range
28.15 – 29.51
Volume / Avg
2.83M / 2.77M
Beta
—

52-week range

$25.92$42.81

SUPN stock today

Shares of Supernus (SUPN) finished higher on Nov 20 at $28.61, a gain of 0.92% or $0.26 per share, versus the S&P 500's 3.70% decline. At this level, SUPN sits near the bottom of its 52-week range of $25.92 to $42.81: 33.2% below the high and 10.4% above the low. SUPN is down 42.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 36.9%.

Supernus has posted a net loss over the last twelve months (EPS of -$0.76), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Supernus

Company profile

Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Jack A. Khattar M.B.A.
Headquarters
Rockville, MD
Employees
827
IPO year
2012

Financial highlights

Full financials

In fiscal 2025, Supernus generated $719.0 million in revenue, up 8.6% from fiscal 2024, its 2nd consecutive year of revenue growth. Supernus reported a net loss of $38.5 million, compared with net income of $73.9 million a year earlier. Gross margin was 89.6% (up from 88.2%) and operating margin -8.7%.

Supernus annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$718.95M$661.82M$607.52M$667.24M$579.77M
Growth+8.63%+8.94%-8.95%+15.09%+11.41%
Net income$-38.55M$73.86M$1.32M$60.71M$53.42M
EPS (diluted)$-0.68$1.32$0.02$1.04$0.98

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$54.14+89.23%

  • Strong buy 2
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $45.00High $87.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 29, 2026
EPS actual vs est.
$0.35 vs $0.34
Surprise
+2.94%

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$8.13
Ex-dividend date
Nov 3, 2026
Pay date
Nov 6, 2026

SUPN news

All SUPN news

Supernus peers

Health Care sector
SUPN peer companies
CompanyPrice% ChgMarket capCompare
ARWRArrowhead Pharmaceuticals Inc.41.37-5.22%$5.85Bvs SUPN
LGNDLigand Pharmaceuticals Incorporated286.85-0.03%$5.74Bvs SUPN
GRFSGrifols S.A. ADR8.15-0.61%$5.55Bvs SUPN
MIRMMirum Pharmaceuticals Inc.96.13+0.65%$6.28Bvs SUPN
ABVXAbivax SA ADR73.20-9.24%$6.41Bvs SUPN
BLTEBelite Bio Inc ADR127.38-15.65%$5.17Bvs SUPN
MANEVeradermics Incorporated119.52-3.92%$5.04Bvs SUPN
AXSMAxsome Therapeutics Inc.129.36-4.66%$6.80Bvs SUPN

Indexes, lists and sector

Supernus stock FAQ

What is Supernus's stock price today?

SUPN last traded at $28.61 as of Nov 20, 4:00 PM EST, up 0.92% on the day. Prices are delayed at least 15 minutes.

Does Supernus pay a dividend?

Yes. Supernus pays $0.00 per share annually. The most recent dividend of $8.13 had an ex-dividend date of Nov 3, 2026.

Who is Supernus's CEO?

Mr. Jack A. Khattar M.B.A. is the chief executive officer of Supernus Inc., which has about 827 employees.

What is the SUPN 52-week high?

The 52-week high for SUPN is $42.81 and the 52-week low is $25.92. The stock is currently 33.2% below its high.

Compare SUPN